







Nonclinical development of CTN001 for treating patients with breast cancer and gastric cancer

Centenaire Bioscience, Inc.

Disease Area	<i>Oncology</i>												
Product Type	Twin Fc-ICE antibody (Biopharmaceutical)												
Indication	<i>Trastuzumab, Pertuzumab or Enhertu-Refractory/relapsed Her2+ or Her2-low breast cancer AND gastric cancer(GC)</i>												
Target	HER2												
Mechanism of Action	<ul style="list-style-type: none">Enhanced engagement of multiple innate immune cells and complements with HER2-expressing tumorsSuperior antibody-mediated functions (ADCC, ADCP/ADCT and CDC)												
Competitiveness	<ul style="list-style-type: none">Innovative Twin Fc-ICE platform for engaging innate immune cells via increased binding to activating Fcγ receptors and Her2 expressing cancer cellsBest-in-class engineered antibody showing superior anti-tumor activity in HER2-low cancers as well as HER2+ cancersGood developability and safety, comparable to conventional IgG1Targeting Enhertu-refractory/relapsed HER2+ and HER2-low patients												
Development Stage	<i>Preclinical (Toxicology studies on-going)</i>												
Route of Administration	IV												
Key Data	<div><div><div><div><div>CTN001 mediated superior antibody-mediated function including ADCC, ADCP and CDC to HER2+ and HER-low tumor cells</div><div><div>ADCC (HER2-low SNU601)</div><div>ADCP (Brest, gastric, lung cancer cells)</div><div>CDC (Brest, gastric, lung cancer cells)</div></div><div><div><i>In vivo</i> efficacy of H01(CTN001) in Her2-low and trastuzumab/Enhertu-resistant tumor models</div><div><div>SNU-5 (HER2-low GC)</div><div>CT26-HER2^{low}</div></div></div><div><div>CTN001 shows a good manufacturability</div><div><table><tr><th>Melting temperature</th><th>Trastuzumab</th><th>Pertuzumab</th><th>CTN001</th></tr><tr><td>T_m1 (Fc)</td><td>68°C</td><td>68°C</td><td>66°C</td></tr><tr><td>T_m2 (Fab)</td><td>81°C</td><td>79°C</td><td>83°C</td></tr></table><p>Melting temperatures of trastuzumab, pertuzumab and CTN001 were analyzed by differential scanning fluorimetry.</p></div><div><p>> 96% monomer purity with platform purification process</p></div></div></div></div></div></div>	Melting temperature	Trastuzumab	Pertuzumab	CTN001	T _m 1 (Fc)	68°C	68°C	66°C	T _m 2 (Fab)	81°C	79°C	83°C
Melting temperature	Trastuzumab	Pertuzumab	CTN001										
T _m 1 (Fc)	68°C	68°C	66°C										
T _m 2 (Fab)	81°C	79°C	83°C										
IP	ANTIGEN BINDING PROTEINS WITH TWO Fc DOMAINS AND USE THEREOF (WO2023068818, KR1020230060546)												

